Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
210 Clinical Trials near Hoover, AL
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerAZD9550 + AZD6234 for Obesity
Vestavia Hills, Alabama
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, GI Disease, Psychosis, Others
Must Not Be Taking:GLP1
360 Participants Needed
TERN-601 for Obesity
Homewood, Alabama
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Endocrinologic Disorders, Others
150 Participants Needed
AZD5004 for Type 2 Diabetes
Vestavia Hills, Alabama
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Retinopathy, Pancreatitis, Others
Must Be Taking:Metformin, SGLT2 Inhibitors
406 Participants Needed
TOUR006 for Chronic Kidney Disease
Birmingham, Alabama
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Active Infection, Immunodeficiency, Heart Failure, Others
143 Participants Needed
Lu AG09222 for Migraine
Hoover, Alabama
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pain Syndromes, Temporomandibular Disorder, Confounding Headaches, Others
Must Not Be Taking:Anti-PACAP
874 Participants Needed
OATD-01 for Sarcoidosis
Birmingham, Alabama
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiac Sarcoidosis, Neuro-sarcoidosis, Others
Must Not Be Taking:QT Prolongation Drugs, Thiazides
96 Participants Needed
Verekitug for Severe Asthma
Birmingham, Alabama
This trial tests a new injectable medication, verekitug (UPB-101), on adults with severe asthma to see if it can reduce asthma attacks and improve breathing.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Recent Hospitalization, Smoking, Infections, Others
Must Be Taking:Inhaled Corticosteroids
479 Participants Needed
Briquilimab for Chronic Hives
Birmingham, Alabama
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.
The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Chronic Urticaria, Anaphylaxis, Others
Must Be Taking:H1-antihistamines, Omalizumab
80 Participants Needed
Pentavalent Meningococcal Vaccine for Meningococcal Disease
Birmingham, Alabama
This trial is testing a new vaccine that protects against five types of meningococcal bacteria in adults and adolescents. The vaccine helps the body learn to fight off these bacteria.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:10 - 25
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Meningitis History, Tuberculosis, Others
1220 Participants Needed
MK-6194 for Vitiligo
Birmingham, Alabama
This trial is testing a new medication called MK-6194 to see if it can help people with non-segmental vitiligo. The goal is to determine if MK-6194 can reduce the white patches on their skin by helping repigment these areas. Researchers will compare the results over several months.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Segmental Vitiligo, Leukotrichia, Infections, Heart Failure, Others
169 Participants Needed
HY209gel for Eczema
Birmingham, Alabama
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Unstable AD, Cancer, Skin Diseases, Others
Must Not Be Taking:Corticosteroids, Cyclosporine, Biologics, Others
210 Participants Needed
AZD4604 for Asthma
Birmingham, Alabama
This trial tests a new asthma medication called AZD4604, which is inhaled regularly using a dry-powder inhaler. It targets adults whose moderate-to-severe asthma is not well-controlled by current treatments. The medication likely works by opening up the airways and reducing inflammation, making it easier to breathe.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Asthma Exacerbation, COVID-19, Others
Must Be Taking:ICS, LABA
340 Participants Needed
Amlitelimab for Atopic Dermatitis/Eczema
Birmingham, Alabama
This trial tests amlitelimab, a medication that may help adults with moderate-to-severe atopic dermatitis respond better to vaccines. It works by improving how the immune system functions.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Immunosuppression, Malignancies, Active Infections, Others
224 Participants Needed
PF-07275315 + PF-07264660 for Eczema
Birmingham, Alabama
This trial is testing two new medicines, PF-07275315 and PF-07264660, given as shots to adults with moderate to severe atopic dermatitis that hasn't improved with other treatments. The goal is to see if these medicines are safe and effective in reducing the symptoms of this itchy red rash.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:SLE, Type 1 Diabetes, IBD, Others
Must Not Be Taking:Systemic Immunosuppressants, Antimicrobials
340 Participants Needed
TARA-002 for Bladder Cancer
Homewood, Alabama
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1).
The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a).
This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF.
Participants will be enrolled into one of 2 cohorts:
Cohort A:
* Participants with CIS (± Ta/T1) who are BCG naive, or
* Participants with CIS (± Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis
Cohort B:
* Participants who are BCG unresponsive
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Penicillin Allergy, Adenocarcinoma, Metastatic Disease, Others
131 Participants Needed
Povorcitinib for Chronic Spontaneous Urticaria
Birmingham, Alabama
This trial is testing a new medication called povorcitinib for adults with a chronic skin condition called CSU. These patients haven't found relief with standard treatments. The medication works by reducing the body's overactive immune response.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Thrombocytopenia, Malignancies, Others
Must Be Taking:Second-generation H1 Antihistamines
136 Participants Needed
Povorcitinib for Asthma
Birmingham, Alabama
This trial is testing a medication called povorcitinib to see if it can help people with lung function problems. The study is looking at three different doses to find out which one works best. The goal is to improve how well the lungs work.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Smoking, Pregnancy, Heart Failure, Others
Must Be Taking:ICS-LABA
240 Participants Needed
RSV mRNA Vaccine for Respiratory Syncytial Virus Immunization
Birmingham, Alabama
This trial tests a new RSV vaccine that uses tiny fat particles to help deliver it into the body. It aims to see if the vaccine is safe and effective in healthy adults aged 18-50 and those aged 60 and older. The vaccine works by teaching the immune system to recognize and fight RSV.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Not Listed
865 Participants Needed
HTD1801 for Non-alcoholic Fatty Liver Disease
Birmingham, Alabama
This trial is testing HTD1801, a medication, to see if it can help adults with NASH and liver fibrosis who also have type 2 diabetes or pre-diabetes. The goal is to see if the medication can reduce liver inflammation and scarring, thereby improving liver health.
Trial Details
Trial Status:Completed
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Fibrosis Stage 4, Alcohol Abuse, Cardiovascular Disease, Others
218 Participants Needed
K-877-ER + CSG452 for NASH
Homewood, Alabama
This trial is testing two new experimental drugs used together to treat adults with a serious liver disease. The combination is expected to be more effective than using each drug alone.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Liver Diseases, Alcohol Use, Others
228 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
Darolutamide + ADT for Metastatic Hormone-Sensitive Prostate Cancer
Homewood, Alabama
The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival.
The researchers want to learn how long it takes for the cancer to get worse (also known as "progression-free survival") by either increasing symptoms, new metastases, PSA rise or death. All participants will be on treatment and take darolutamide with ADT until their cancer spreads, they have a medical problem, or they leave the study. The results will then be compared with patients' results from another study who received ADT alone (CHAARTED).
This study will also assess safety by gathering adverse event information throughout the duration of the study. An adverse event is any medical problem, related or not to study treatment that a participant has during a study.
The study drug, darolutamide, is already available for doctors to prescribe to patients with prostate cancer that has not yet spread to other parts of the body. It works by blocking a protein called a receptor from attaching to a hormone called androgen that is found in men. This protein can also be found in prostate cancer cells. ADT is a treatment that doctors are currently able to prescribe to patients with mHSPC. ADT is used to lower the amount of the androgen hormone.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Recent Malignancy, Cardiac Events, Brain Metastases, Others
Must Be Taking:ADT
223 Participants Needed
SAR441344 for Lupus
Birmingham, Alabama
This trial is testing a new drug called SAR441344 to see if it can help adults aged 18-70 with active Systemic Lupus Erythematosus (SLE). The drug aims to reduce symptoms by calming the immune system.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Lupus Nephritis, Neuropsychiatric SLE, Thromboembolic Events, Serious Infections, Others
Must Be Taking:Standard Of Care
116 Participants Needed
Sotorasib for Advanced Non-Small Cell Lung Cancer
Birmingham, Alabama
The main objective of this study is to evaluate the tumor objective response rate (ORR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in participants who receive sotorasib at either 960 mg daily or 240 mg daily whose tumors are programmed death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) \< 1% and/or harbor a serine/threonine kinase 11 (STK11) co-mutation, in a subgroup of participants with PD-L1 \< 1% and in a subgroup of participants with STK11 co-mutation.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Small-cell Lung Cancer, Myocardial Infarction, Others
Must Not Be Taking:Proton-pump Inhibitors, H2 Antagonists
42 Participants Needed
Afimetoran for Lupus
Birmingham, Alabama
This trial is testing a new medication called Afimetoran to help people with active Systemic Lupus Erythematosus (SLE). The goal is to see if it can safely reduce symptoms by calming down the immune system. The study will also provide data on its effectiveness and safety over time.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Lupus Nephritis, Neuropsychiatric Lupus, Mixed Connective Tissue Disease, Antiphospholipid Syndrome
268 Participants Needed
AZD9833 vs Fulvestrant for Advanced Breast Cancer
Birmingham, Alabama
This trial compares a new pill (AZD9833) with an existing injection for treating advanced breast cancer in post-menopausal women. It targets women with a specific type of breast cancer that relies on estrogen to grow. Both treatments work by blocking estrogen receptors to slow down or stop cancer growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cardiovascular Issues, CNS Disease, Others
Must Not Be Taking:Hormone Therapy, CYP Inhibitors
240 Participants Needed
BMS-986368 for Alzheimer's Disease
Homewood, Alabama
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:55 - 90
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Schizoaffective, Others
120 Participants Needed
mRNA-1345 Vaccine for Respiratory Syncytial Virus
Birmingham, Alabama
This trial is testing a new vaccine called mRNA-1345 that aims to protect against a lung infection virus known as RSV. The study focuses on pregnant women and their newborns. The vaccine works by teaching the body to recognize and fight the virus using a small piece of genetic material. mRNA-1345 is among the most promising RSV vaccines currently being tested.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Anaphylaxis, Drug Abuse, Fever, Others
Must Not Be Taking:MRNA Vaccines
360 Participants Needed
Psilocybin for Demoralization
Birmingham, Alabama
The purpose of the present study is to evaluate the feasibility, initial signals of efficacy, and potential mechanisms of action of "microdoses" of psilocybin (i.e., low doses of psilocybin that are not believed to produce mystical-type, transcendent, hallucinogenic, or other overtly salient subjective effects that limit functionality) in the treatment of moderate to severe demoralization (feelings of hopelessness and meaningless that frequently accompany medical illness and other life hardship).
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:25 - 65
Key Eligibility Criteria
Disqualifiers:Hypertension, Pregnancy, Psychotic Disorders, Others
Must Not Be Taking:ADHD Meds, Antidepressants, Antipsychotics, Others
60 Participants Needed
Psilocybin for Fibromyalgia
Birmingham, Alabama
This trial is testing if psilocybin, a substance from certain mushrooms, can help people with fibromyalgia by reducing their pain and improving their mood. The treatment works by changing how the brain processes information and emotions. Psilocybin is a naturally occurring substance found in certain mushrooms, known for its potential therapeutic benefits for depression and anxiety.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:25 - 65
Sex:Female
Key Eligibility Criteria
Disqualifiers:Males, Psychotic Disorders, Bipolar, Others
Must Not Be Taking:Opioids, Antidepressants, Antipsychotics, Others
30 Participants Needed
High Intensity Exercise for Cerebral Palsy
Homewood, Alabama
This study is investigating the potential effects of a high-intensity home-exercise program among children with cerebral palsy. The program includes rhythmic movements to music that are adapted for wheelchair uses and age-appropriate themes. This project has the potential to address a large knowledge gap in the extant literature, because there are no widely accessible, evidence-based, enjoyable, and age-appropriate modalities for improving cardiovascular fitness or cardiometabolic health among children with disabilities who have mobility disabilities.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:6 - 17
Key Eligibility Criteria
Disqualifiers:Physically Active, Blindness, Deafness, Others
50 Participants Needed
Know someone looking for new options?
Spread the word